High remission rate in T-cell prolymphocytic leukemia with CAMPATH-1H.

@article{Dearden2001HighRR,
  title={High remission rate in T-cell prolymphocytic leukemia with CAMPATH-1H.},
  author={C. Dearden and E. Matutes and B. Cazin and G. Tj{\o}nnfjord and A. Parreira and B. Nomdedeu and P. Leoni and F. J. Clark and D. Radia and S. M. Rassam and T. Roques and N. Ketterer and V. Brito-Babapulle and M. Dyer and D. Catovsky},
  journal={Blood},
  year={2001},
  volume={98 6},
  pages={
          1721-6
        }
}
  • C. Dearden, E. Matutes, +12 authors D. Catovsky
  • Published 2001
  • Medicine
  • Blood
  • T-cell prolymphocytic leukemia (T-PLL) is a chemotherapy-resistant malignancy with a median survival of 7.5 months. Preliminary results indicated a high remission induction rate with the human CD52 antibody, CAMPATH-1H. This study reports results in 39 patients with T-PLL treated with CAMPATH-1H between March 1993 and May 2000. All but 2 patients had received prior therapy with a variety of agents, including 30 with pentostatin; none achieved complete remission (CR). CAMPATH-1H (30 mg) was… CONTINUE READING
    281 Citations
    T-cell prolymphocytic leukemia
    • 37
    • Highly Influenced
    How I treat prolymphocytic leukemia.
    • 103
    • PDF
    B- and T-cell prolymphocytic leukemia: antibody approaches.
    • C. Dearden
    • Medicine
    • Hematology. American Society of Hematology. Education Program
    • 2012
    • 10
    • PDF
    Where do we currently stand with T-cell prolymphocytic leukemia?
    Dual dependence on BCL2 and MCL1 in T-cell prolymphocytic leukemia.
    • 1
    • PDF
    Allogeneic hematopoietic cell transplant for prolymphocytic leukemia.
    • M. Kalaycio, M. Kukreja, +13 authors M. Arora
    • Medicine
    • Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation
    • 2010
    • 29
    Peripheral T-cell lymphomas: diagnosis and management.
    • 24

    References

    SHOWING 1-10 OF 22 REFERENCES
    Treatment of T-cell prolymphocytic leukemia with human CD52 antibody.
    • R. Pawson, M. Dyer, +7 authors D. Catovsky
    • Medicine
    • Journal of clinical oncology : official journal of the American Society of Clinical Oncology
    • 1997
    • 190
    The role of pentostatin in the treatment of T-cell malignancies: analysis of response rate in 145 patients according to disease subtype.
    • 164
    Subcutaneous CAMPATH‐1H in fludarabine‐resistant/relapsed chronic lymphocytic and B‐prolymphocytic leukaemia
    • 145
    Phase II multicenter study of human CD52 antibody in previously treated chronic lymphocytic leukemia. European Study Group of CAMPATH-1H Treatment in Chronic Lymphocytic Leukemia.
    • 535
    CAMPATH-1H monoclonal antibody in therapy for previously treated low-grade non-Hodgkin's lymphomas: a phase II multicenter study. European Study Group of CAMPATH-1H Treatment in Low-Grade Non-Hodgkin's Lymphoma.
    • 243
    Indolent course as a relatively frequent presentation in T‐prolymphocytic leukaemia
    • 118
    Treatment of T prolymphocytic leukemia with allogeneic bone marrow transplantation
    • 35
    • PDF